Activating mutations in EGFR are one of the most prevalent oncogenic drivers in NSCLC accounting for 15–20% of adenocarcinoma patients in Caucasian populations, with an increased prevalence of up to 50% of patients in Asian populations [12–15]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.